DarioHealthDRIO +1.17%62 EBITDA Margin % is -116.74% as of Mar. 2026. GuruFocus rates DRIO with a GF Score™ of 62/100 and a GF Value™ of $7.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, DarioHealth ranks worse than 92.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. DarioHealth's EBITDA for the
three
months ended in Mar. 2026 was $-6.52 Mil. DarioHealth's Revenue for the
three
months ended in Mar. 2026 was $5.58 Mil. Therefore, DarioHealth's EBITDA margin for the quarter that ended in Mar. 2026 was -116.74%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
DarioHealth EBITDA Margin % Related Terms
DarioHealth EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for DarioHealth's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRIO vs BEAT, ONMD, VASO: EBITDA Margin % Comparison
For the Health Information Services subindustry, DarioHealth's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DarioHealth EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where DarioHealth's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DarioHealth (DRIO) has a EBITDA Margin % of -116.74% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DarioHealth and its competitors. According to the industry distribution chart, DarioHealth ranks #619 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 92.7%.
Is DarioHealth's EBITDA Margin % too high?
DarioHealth's current EBITDA Margin % is -116.74%. Based on the distribution chart, DarioHealth ranks #619 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DarioHealth has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DarioHealth's EBITDA Margin % compare to BEAT and ONMD?
According to the Healthcare Providers & Services industry distribution chart, DarioHealth ranks #619 out of 668 companies for EBITDA Margin %. This places DarioHealth in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DarioHealth and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DarioHealth's current EBITDA Margin % is -116.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DarioHealth stock overvalued right now?
Based on GuruFocus' analysis, DarioHealth (DRIO) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.16, compared to a current price of $6.06 — trading 15.4% below its estimated fair value. The current EBITDA Margin % is -116.74%. DarioHealth's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DarioHealth (DRIO), the current EBITDA Margin % is -116.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DarioHealth (DRIO) Overvalued in 2026?
Based on GuruFocus' analysis, DarioHealth stock appears to be undervalued.
The current stock price of $6.06 is trading 15.4% below its estimated GF Value™ of $7.16.
GuruFocus considers DarioHealth to be Modestly Undervalued.
Key valuation signals for DRIO:
EBITDA Margin %: -116.74%
GF Value™: $7.16 vs. price of $6.06 (15.4% below fair value)
No single metric tells the full story. See the DRIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
62GF Score
Get the complete analysis for DRIO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRIO has been successfully added to your 
